Avanir cites 'encouraging' progress in PhIII program for Alzheimer's agitation
Avanir Pharma has chalked up a win for the first late-stage study for AVP-786 in Alzheimer’s agitation, laying the groundwork for a high-risk, high-reward Phase …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.